Maureen P.M.H. Rutten-van Mölken
- Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trialBy Martine Hoogendoorn, Maiwenn J. Al, Kai-Michael Beeh, David Bowles, J. Matthias Graf von der Schulenburg, Juliane Lungershausen, Brigitta U. Monz, Hendrik Schmidt, Claus Vogelmeier and Maureen P.M.H. Rutten-van MölkenMartine Hoogendoorn*Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The NetherlandsMaiwenn J. Al*Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The NetherlandsKai-Michael Beeh#INSAF Respiratory Research Institute, WiesbadenDavid Bowles¶Fakultät für Gesundheitswissenschaften, Gesundheitsökonomie und Gesundheitsmanagement, Universität Bielefeld, BielefeldJ. Matthias Graf von der Schulenburg+Institut für Versicherungsbetriebslehre, Leibniz Universität Hannover, HanoverJuliane Lungershausen§Boehringer Ingelheim International GmbH, IngelheimBrigitta U. Monz§Boehringer Ingelheim International GmbH, IngelheimHendrik Schmidt§Boehringer Ingelheim International GmbH, IngelheimClaus VogelmeierfDivision of Pulmonary Diseases, University Hospital Giessen en Marburg, Marburg, GermanyMaureen P.M.H. Rutten-van Mölken*Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands
- Tiotropium vs salmeterol in GOLD II and maintenance-naïve COPD patients: Subgroup analyses of POET-COPD™ trialBy Kai M. Beeh, Claus Vogelmeier, Maureen P.M.H. Rutten-van Mölken, Klaus F. Rabe, Thomas Glaab, Fee Rühmkorf, Hendrik Schmidt and Leonardo M. FabbriKai M. Beeh1Dept of Internal and Pulmonary Medicine, Insaf Respiratory Research Institute, D 65187 Wiesbaden, GermanyClaus Vogelmeier2Division for Pulmonary Diseases, Hospital of the Universities of Giessen and Marburg, Marburg, GermanyMaureen P.M.H. Rutten-van Mölken3Dept of Health Economics, Institute for Medical Technology Assessment (IMTA), Erasmus University, Rotterdam, NetherlandsKlaus F. Rabe4Dept of Pneumologie, Grosshansdorf Hospital, Grosshansdorf, GermanyThomas Glaab5Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, GermanyFee Rühmkorf5Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, GermanyHendrik Schmidt5Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, GermanyLeonardo M. Fabbri6Dept of Medical and Surgical Specialties, University of Modena & Reggio Emilia, Modena, Italy
- Do exacerbation outcomes in the POET-COPD™ trial differ between regions?By Maureen P.M.H. Rutten-van Mölken, Leonardo M. Fabbri, Klaus F. Rabe, Harald Kögler, Thomas Glaab, Hendrik Schmidt, Kai M. Beeh and Claus VogelmeierMaureen P.M.H. Rutten-van Mölken1Department of Health Economics, Institute for Medical Technology Assessment (IMTA), Erasmus University, Rotterdam, NetherlandsLeonardo M. Fabbri2Department of Medical and Surgical Specialties, University of Modena & Reggio Emilia, Modena, ItalyKlaus F. Rabe3Department of Pneumologie, Grosshansdorf Hospital, Grosshansdorf, GermanyHarald Kögler4Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyThomas Glaab4Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyHendrik Schmidt4Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyKai M. Beeh5Department of Internal and Pulmonary Medicine, Insaf Respiratory Research Institute, Wiesbaden, GermanyClaus Vogelmeier6Division for Pulmonary Diseases, Hospital of the Universities of Giessen and Marburg, Marburg, Germany
- Baseline characteristics of patients with frequent exacerbations in the POET-COPD™ trialBy Leonardo M. Fabbri, Claus Vogelmeier, Maureen P.M.H. Rutten-van Mölken, Klaus F. Rabe, Thomas Glaab, Fee Rühmkorf, Hendrik Schmidt and Kai M. BeehLeonardo M. Fabbri1Dept. of Medical & Surgical Specialities, University of Modena & Reggio Emilia, Modena, ItalyClaus Vogelmeier2Division of Pulmonary Diseases, Hospital of the Universities of Giessen and Marburg, Marburg, GermanyMaureen P.M.H. Rutten-van Mölken3Dept. of Health Economics, Institute for Medical Technology Assessment (IMTA), Erasmus University, Rotterdam, NetherlandsKlaus F. Rabe4Dept. of Pneumologie, Grosshansdorf Hospital, Grosshansdorf, GermanyThomas Glaab5Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, GermanyFee Rühmkorf5Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, GermanyHendrik Schmidt5Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, GermanyKai M. Beeh6Dept. of Internal and Pulmonary Medicine, Insaf Respiratory Research Institute, Wiesbaden, Germany
- Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trialBy Martine Hoogendoorn, Maiwenn J. Al, Kai-Michael Beeh, David Bowles, J. Matthias Graf von der Schulenburg, Juliane Lungershausen, Brigitta U. Monz, Hendrik Schmidt, Claus Vogelmeier and Maureen P.M.H. Rutten-van MölkenArticle | Published in 2012 in European Respiratory JournalMartine HoogendoornMaiwenn J. AlKai-Michael BeehDavid BowlesJ. Matthias Graf von der SchulenburgJuliane LungershausenBrigitta U. MonzHendrik SchmidtClaus VogelmeierMaureen P.M.H. Rutten-van Mölken
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.